|
Volumn 2, Issue 4, 2001, Pages 472-476
|
Antifungal antibodies: A new approach to the treatment of systemic candidiasis
|
Author keywords
Antifungal antibodies; Candida; Hsp90; Mycograb
|
Indexed keywords
AMPHOTERICIN B;
AMPHOTERICIN B LIPID COMPLEX;
ANTIFUNGAL AGENT;
FUNGUS ANTIBODY;
HEAT SHOCK PROTEIN;
HEAT SHOCK PROTEIN 90;
MANNOPROTEIN;
MONOCLONAL ANTIBODY;
MYCOGRAB;
PLACEBO;
RECOMBINANT ANTIBODY;
UNCLASSIFIED DRUG;
ANTIFUNGAL ACTIVITY;
CANDIDA;
CANDIDIASIS;
CELLULAR IMMUNITY;
CLINICAL TRIAL;
COST;
DOSE RESPONSE;
DOSE TIME EFFECT RELATION;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG DISTRIBUTION;
DRUG HALF LIFE;
DRUG MANUFACTURE;
DRUG MONITORING;
DRUG POTENTIATION;
DRUG SAFETY;
DRUG TARGETING;
DRUG TOLERANCE;
GENETIC ENGINEERING;
HIGH RISK PATIENT;
HUMAN;
IMMUNOHISTOCHEMISTRY;
MINIMUM INHIBITORY CONCENTRATION;
NONHUMAN;
PROPHYLAXIS;
REVIEW;
SIDE EFFECT;
SYSTEMIC DISEASE;
TOXICITY TESTING;
AMPHOTERICIN B;
ANIMALS;
ANTIBODIES, FUNGAL;
ANTIBODIES, MONOCLONAL;
CANDIDIASIS;
DRUG THERAPY, COMBINATION;
HSP90 HEAT-SHOCK PROTEINS;
HUMANS;
MEMBRANE GLYCOPROTEINS;
MICE;
RECOMBINANT PROTEINS;
|
EID: 0035050102
PISSN: 09678298
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (56)
|
References (42)
|